Artificial Intelligence-based

Clinical Decision Support for Diabetes and Obesity

Praedigo tackles the high burden of diabetes and obesity comorbidities by using cutting-edge AI models trained on thousands of patients to support physicians in an early diagnosis.

Diabetes can lead to serious comorbidities

Chronic Kidney Disease

Around one of three T2DM patients develops chronic kidney disease¹


Diabetic Polyneuropathy

Half of the diabetes patients are estimated to develop diabetic polyneuropathy²,


Cardiovascular Diseases

Around one of three T2DM patients develops cardiovascular diseases³


88% of diabetes and obesity patients do have at least two comorbidities ⁴⁻⁵

Our AI Models

Praedigo detects diabetes comorbidities in undiagnosed patients

Our models correctly identify 82% of CKD patients and 79% of DPN patients, while keeping the number of false diagnosis moderately low. In contrast, the current healthcare systems only diagnose up to 35%⁶ of stage 3 CKDs and 23%² of DPNs.

Further, we interpret our models to identify important patterns and events that will improve the diagnosis of diabetes comorbidities further.

Benefits of Praedigo’s Clinical Decision Support


Improve the quality of life of diabetes patients

Medical Units

Support physicians in their decision-making and reduce time and cost efforts


Early identification of patients and simplified patient recruitment for clinical trials

Health Insurance

Reduce costs for the healthcare system by earlier diagnosis of comorbidities

We are open for collaborations!

If you are interested in Praedigo we would be happy to discuss potential collaborations. Reach out to us.


  1. United States Renal Data System. 2023 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2023.
  2. Ziegler D, et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Res Clin Pract. 2022 Apr;186:109063. doi: 10.1016/j.diabres.2021.109063. Epub 2021 Sep 20. PMID: 34547367.
  3. Einarson, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol 17, 83 (2018).
  4. Apovian CM, Aronne LJ, Barenbaum S. Obesity-Related Comorbidities . April 23, 2024. Accessed June 04, 2024.
  5. Shuvo SD, Hossen MT, Riazuddin M, Hossain MS, Mazumdar S, Parvin R, Elahi MT. Prevalence of comorbidities and its associated factors among type-2 diabetes patients: a hospital-based study in Jashore District, Bangladesh. BMJ Open. 2023.
  6. Schneider, Markus P., et al. „1213-P: REVEAL-CKD: Undiagnosed Chronic Kidney Disease in Patients with Type 2 Diabetes in Germany and France.“ Diabetes 71. Supplement_1 (2022).